# Brad H. Rovin

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/brad-h-rovin/

## Facts

| Field | Value |
| --- | --- |
| Citations | 39,374 |
| Field | Renal Diseases and Glomerulopathies |
| h-index | 90 |
| i10-index | 315 |
| Last Known Institution | The Ohio State University Wexner Medical Center |
| OpenAlex ID | https://openalex.org/A5042356850 |
| ORCID iD | 0000-0001-5639-0210 |
| Works | 654 |

## Researcher papers

Showing 12 of 32.

- [Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach](https://scholariq.org/papers/differential-diagnosis-of-glomerular-disease-a-systematic-and-inclusive-approach/)
- [KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases](https://scholariq.org/papers/kdigo-2021-clinical-practice-guideline-for-the-management-of-glomerular-diseases/)
- [Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study](https://scholariq.org/papers/efficacy-and-safety-of-rituximab-in-patients-with-active-proliferative-lupus/)
- [The Influence of <i>CCL3L1</i> Gene-Containing Segmental Duplications on HIV-1/AIDS Susceptibility](https://scholariq.org/papers/the-influence-of-i-ccl3l1-i-gene-containing-segmental-duplications-on-hiv-1-aids/)
- [Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis](https://scholariq.org/papers/two-year-randomized-controlled-trial-of-belimumab-in-lupus-nephritis/)
- [Update on Lupus Nephritis](https://scholariq.org/papers/update-on-lupus-nephritis/)
- [Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases](https://scholariq.org/papers/executive-summary-of-the-kdigo-2021-guideline-for-the-management-of-glomerular/)
- [An atlas of healthy and injured cell states and niches in the human kidney](https://scholariq.org/papers/an-atlas-of-healthy-and-injured-cell-states-and-niches-in-the-human-kidney/)
- [Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial](https://scholariq.org/papers/efficacy-and-safety-of-voclosporin-versus-placebo-for-lupus-nephritis-aurora-1-a/)
- [Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy](https://scholariq.org/papers/rituximab-or-cyclosporine-in-the-treatment-of-membranous-nephropathy/)
- [Update on Lupus Nephritis: Core Curriculum 2020](https://scholariq.org/papers/update-on-lupus-nephritis-core-curriculum-2020/)
- [A Novel Polymorphism in the MCP-1 Gene Regulatory Region That Influences MCP-1 Expression](https://scholariq.org/papers/a-novel-polymorphism-in-the-mcp-1-gene-regulatory-region-that-influences-mcp-1/)

## Researcher topics

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Vasculitis and related conditions](https://scholariq.org/topics/vasculitis-and-related-conditions/)
- [Liver Diseases and Immunity](https://scholariq.org/topics/liver-diseases-and-immunity/)

## Researcher university

- [The Ohio State University Wexner Medical Center](https://scholariq.org/institutions/the-ohio-state-university-wexner-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.